224 related articles for article (PubMed ID: 18250026)
41. Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy.
Jeraj R; Bradshaw T; Simončič U
J Nucl Med; 2015 Nov; 56(11):1752-65. PubMed ID: 26383148
[TBL] [Abstract][Full Text] [Related]
42. Computed Tomography and Magnetic Resonance Imaging.
Bernsen MR; van Straten M; Kotek G; Warnert EAH; Haeck JC; Ruggiero A; Wielopolski PA; Krestin GP
Recent Results Cancer Res; 2020; 216():31-110. PubMed ID: 32594384
[TBL] [Abstract][Full Text] [Related]
43. [Computational medical imaging (radiomics) and potential for immuno-oncology].
Sun R; Limkin EJ; Dercle L; Reuzé S; Zacharaki EI; Chargari C; Schernberg A; Dirand AS; Alexis A; Paragios N; Deutsch É; Ferté C; Robert C
Cancer Radiother; 2017 Oct; 21(6-7):648-654. PubMed ID: 28865968
[TBL] [Abstract][Full Text] [Related]
44. The molecular biology of cancer.
Bertram JS
Mol Aspects Med; 2000 Dec; 21(6):167-223. PubMed ID: 11173079
[TBL] [Abstract][Full Text] [Related]
45. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.
Shigdar S; Lin J; Li Y; Yang CJ; Wei M; Zhus Y; Liu H; Duan W
Ther Deliv; 2012 Feb; 3(2):227-44. PubMed ID: 22834199
[TBL] [Abstract][Full Text] [Related]
46. Optical Imaging Modalities: Principles and Applications in Preclinical Research and Clinical Settings.
Pirovano G; Roberts S; Kossatz S; Reiner T
J Nucl Med; 2020 Oct; 61(10):1419-1427. PubMed ID: 32764124
[TBL] [Abstract][Full Text] [Related]
47. Clinical protein science in translational medicine targeting malignant melanoma.
Gil J; Betancourt LH; Pla I; Sanchez A; Appelqvist R; Miliotis T; Kuras M; Oskolas H; Kim Y; Horvath Z; Eriksson J; Berge E; Burestedt E; Jönsson G; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Murillo JR; Sugihara Y; Welinder C; Wieslander E; Lee B; Lindberg H; Pawłowski K; Kwon HJ; Doma V; Timar J; Karpati S; Szasz AM; Németh IB; Nishimura T; Corthals G; Rezeli M; Knudsen B; Malm J; Marko-Varga G
Cell Biol Toxicol; 2019 Aug; 35(4):293-332. PubMed ID: 30900145
[TBL] [Abstract][Full Text] [Related]
48. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
50. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
51. The evolving role of nuclear molecular imaging in cancer.
Kurdziel K; Ravizzini G; Croft B; Tatum J; Choyke P; Kobayashi H
Expert Opin Med Diagn; 2008 Jul; 2(7):829-842. PubMed ID: 19122861
[TBL] [Abstract][Full Text] [Related]
52. Cancer molecular markers: A guide to cancer detection and management.
Nair M; Sandhu SS; Sharma AK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):39-55. PubMed ID: 29428478
[TBL] [Abstract][Full Text] [Related]
53. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
Yim R
Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
[TBL] [Abstract][Full Text] [Related]
54. Molecular pathology in oncology--the AstraZeneca perspective.
Campbell DA; Carmichael J; Chopra R
Pharmacogenomics; 2004 Dec; 5(8):1167-73. PubMed ID: 15584883
[TBL] [Abstract][Full Text] [Related]
55. Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.
Lim MS; Beyer T; Babayan A; Bergmann M; Brehme M; Buyx A; Czernin J; Egger G; Elenitoba-Johnson KSJ; Gückel B; Jačan A; Haslacher H; Hicks RJ; Kenner L; Langanke M; Mitterhauser M; Pichler BJ; Salih HR; Schibli R; Schulz S; Simecek J; Simon J; Soares MO; Stelzl U; Wadsak W; Zatloukal K; Zeitlinger M; Hacker M
Mol Imaging Biol; 2020 Feb; 22(1):47-65. PubMed ID: 31049831
[TBL] [Abstract][Full Text] [Related]
56. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
57. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential.
Mercer JR
J Pharm Pharm Sci; 2007; 10(2):180-202. PubMed ID: 17706177
[TBL] [Abstract][Full Text] [Related]
58. Molecular imaging.
Weissleder R; Mahmood U
Radiology; 2001 May; 219(2):316-33. PubMed ID: 11323453
[TBL] [Abstract][Full Text] [Related]
59. Molecular MR imaging in oncology.
Bradbury M; Hricak H
Magn Reson Imaging Clin N Am; 2005 May; 13(2):225-40. PubMed ID: 15935309
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
